Literature DB >> 24023066

EGFR lung cancer mutants get specialized.

Peter Littlefield1, Natalia Jura.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 24023066      PMCID： PMC3780895          DOI： 10.1073/pnas.1314719110

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN： 0027-8424            Impact factor:   11.205


× No keyword cloud information.
  14 in total

1.  Structures of lung cancer-derived EGFR mutants and inhibitor complexes: mechanism of activation and insights into differential inhibitor sensitivity.

Authors:  Cai-Hong Yun; Titus J Boggon; Yiqun Li; Michele S Woo; Heidi Greulich; Matthew Meyerson; Michael J Eck
Journal:  Cancer Cell       Date:  2007-03       Impact factor: 31.743

2.  Mechanism for activation of mutated epidermal growth factor receptors in lung cancer.

Authors:  Monica Red Brewer; Cai-Hong Yun; Darson Lai; Mark A Lemmon; Michael J Eck; William Pao
Journal:  Proc Natl Acad Sci U S A       Date:  2013-09-09       Impact factor: 11.205

3.  An allosteric mechanism for activation of the kinase domain of epidermal growth factor receptor.

Authors:  Xuewu Zhang; Jodi Gureasko; Kui Shen; Philip A Cole; John Kuriyan
Journal:  Cell       Date:  2006-06-16       Impact factor: 41.582

4.  EGF-independent activation of cell-surface EGF receptors harboring mutations found in gefitinib-sensitive lung cancer.

Authors:  S H Choi; J M Mendrola; M A Lemmon
Journal:  Oncogene       Date:  2006-09-04       Impact factor: 9.867

5.  ErbB-1 and ErbB-2 acquire distinct signaling properties dependent upon their dimerization partner.

Authors:  M A Olayioye; D Graus-Porta; R R Beerli; J Rohrer; B Gay; N E Hynes
Journal:  Mol Cell Biol       Date:  1998-09       Impact factor: 4.272

6.  EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib.

Authors:  William Pao; Vincent Miller; Maureen Zakowski; Jennifer Doherty; Katerina Politi; Inderpal Sarkaria; Bhuvanesh Singh; Robert Heelan; Valerie Rusch; Lucinda Fulton; Elaine Mardis; Doris Kupfer; Richard Wilson; Mark Kris; Harold Varmus
Journal:  Proc Natl Acad Sci U S A       Date:  2004-08-25       Impact factor: 11.205

7.  EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.

Authors:  J Guillermo Paez; Pasi A Jänne; Jeffrey C Lee; Sean Tracy; Heidi Greulich; Stacey Gabriel; Paula Herman; Frederic J Kaye; Neal Lindeman; Titus J Boggon; Katsuhiko Naoki; Hidefumi Sasaki; Yoshitaka Fujii; Michael J Eck; William R Sellers; Bruce E Johnson; Matthew Meyerson
Journal:  Science       Date:  2004-04-29       Impact factor: 47.728

8.  Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib.

Authors:  Thomas J Lynch; Daphne W Bell; Raffaella Sordella; Sarada Gurubhagavatula; Ross A Okimoto; Brian W Brannigan; Patricia L Harris; Sara M Haserlat; Jeffrey G Supko; Frank G Haluska; David N Louis; David C Christiani; Jeff Settleman; Daniel A Haber
Journal:  N Engl J Med       Date:  2004-04-29       Impact factor: 91.245

9.  Structure of the epidermal growth factor receptor kinase domain alone and in complex with a 4-anilinoquinazoline inhibitor.

Authors:  Jennifer Stamos; Mark X Sliwkowski; Charles Eigenbrot
Journal:  J Biol Chem       Date:  2002-08-23       Impact factor: 5.157

10.  Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain.

Authors:  William Pao; Vincent A Miller; Katerina A Politi; Gregory J Riely; Romel Somwar; Maureen F Zakowski; Mark G Kris; Harold Varmus
Journal:  PLoS Med       Date:  2005-02-22       Impact factor: 11.069
View more
  4 in total

1.  RETRACTED: An ATP-competitive inhibitor modulates the allosteric function of the HER3 pseudokinase.

Authors:  Peter Littlefield; Mark M Moasser; Natalia Jura
Journal:  Chem Biol       Date:  2014-03-20

2.  Mechanistic Insights into R776H Mediated Activation of Epidermal Growth Factor Receptor Kinase.

Authors:  Zheng Ruan; Natarajan Kannan
Journal:  Biochemistry       Date:  2015-07-06       Impact factor: 3.162

3.  Structure-based network analysis of activation mechanisms in the ErbB family of receptor tyrosine kinases: the regulatory spine residues are global mediators of structural stability and allosteric interactions.

Authors:  Kevin A James; Gennady M Verkhivker
Journal:  PLoS One       Date:  2014-11-26       Impact factor: 3.240

4.  CUL4A overexpression enhances lung tumor growth and sensitizes lung cancer cells to erlotinib via transcriptional regulation of EGFR.

Authors:  Yunshan Wang; Pengju Zhang; Ziming Liu; Qin Wang; Mingxin Wen; Yuli Wang; Hongtu Yuan; Jian-Hua Mao; Guangwei Wei
Journal:  Mol Cancer       Date:  2014-11-21       Impact factor: 27.401
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.